Skip to main content
. 2019 May 23;125(18):3225–3233. doi: 10.1002/cncr.32200

Table 3.

Adjusted HRs of Developing IBC in the Same Quadrant of the Same Breast as the Original DCIS and IBC in the Ipsilateral Breast Away From the Original DCIS or the Contralateral Breast According to Race and Ethnicity in Women With DCIS in SEER, 1990‐2015

Person‐y All Second Invasive Eventsa ER+ or PR+ ER– and PR–
Cases, No. HRb (95% CI) Cases, No. HRb (95% CI) Cases, No. HRb (95% CI)
IBC in ipsilateral breast away from original DCIS and in contralateral breast White 971,003 4741 1.00 3776 1.00 630 1.00
Black 126,291 755 1.34 (1.24‐1.45) 547 1.24 (1.13‐1.36) 149 1.93 (1.60‐2.40)
Asian 125,104 648 1.06 (0.97‐1.17) 497 0.99 (0.89‐1.10) 107 1.45 (1.15‐1.82)
Hispanic 98,900 489 1.05 (0.95‐1.16) 388 1.05 (0.94‐1.17) 71 1.14 (0.88‐1.47)
P heterogeneity < .0001
IBC in same quadrant of same breast as original DCIS White 709,275 431 1.00 327 1.00 62 1.00
Black 89,081 83 1.51 (1.18‐1.93) 63 1.47 (1.10‐1.95) 11 1.48 (0.75‐2.90)
Asian 86,294 71 1.15 (0.87‐1.52) 55 1.16 (0.84‐1.59) 13 1.49 (0.75‐2.98)
Hispanic 72,785 60 1.16 (0.88‐1.54) 47 1.22 (0.89‐1.67) 12 1.63 (0.85‐3.13)
P heterogeneity = .80

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hazard ratio; IBC, invasive breast cancer; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.

a

Second IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.

b

Hazard ratios were adjusted for the following: age (20‐39, 40‐49, 50‐59, 60‐69, or ≥70 years) and year of the primary DCIS diagnosis (1990‐1999, 2000‐2009, or 2010‐2015); registry; treatment for primary DCIS (no surgical treatment, breast‐conserving surgery alone, breast‐conserving surgery followed by radiation therapy, mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2‐5 cm, ≥5 cm, or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone receptor expression (positive, negative, or unknown).